| scholarly article | Q13442814 |
| P50 | author | Eric A Macklin | Q45310572 |
| Shafeeq S Ladha | Q58144250 | ||
| Terry Heiman-Patterson | Q63214703 | ||
| Jonathan D Glass | Q88095339 | ||
| Hiroshi Mitsumoto | Q90084178 | ||
| Merit E Cudkowicz | Q95746107 | ||
| P2093 | author name string | Robert Lawson | |
| Hong Yu | |||
| Ericka P Simpson | |||
| Jonathan Katz | |||
| Tahseen Mozaffar | |||
| Anne-Marie Wills | |||
| Jane Hubbard | |||
| Rup Tandan | |||
| Benjamin Brooks | |||
| Jau-Shin Lou | |||
| Daniela Grasso | |||
| Deborah Gelinas | |||
| Gregory P Hanes | |||
| Katy Mahoney | |||
| MDA Clinical Research Network | |||
| P2860 | cites work | Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids | Q29614194 |
| No benefit of dietary restriction on disease onset or progression in amyotrophic lateral sclerosis Cu/Zn-superoxide dismutase mutant mice | Q33865534 | ||
| Definition and classification of cancer cachexia: an international consensus | Q34162846 | ||
| Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis | Q34187004 | ||
| Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death | Q34375696 | ||
| Energy intake and amyotrophic lateral sclerosis | Q34582888 | ||
| Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre | Q36425117 | ||
| Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort | Q36687156 | ||
| Premorbid body mass index and risk of amyotrophic lateral sclerosis | Q36737158 | ||
| Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model | Q37285915 | ||
| Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q37613342 | ||
| Energy metabolism in amyotrophic lateral sclerosis | Q37805077 | ||
| Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients | Q37907556 | ||
| EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force | Q37931374 | ||
| The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials | Q38074456 | ||
| Nutrition management of amyotrophic lateral sclerosis | Q38087150 | ||
| The ALS Nutrition/NIPPV Study: design, feasibility, and initial results | Q39789293 | ||
| Nutritional factors in the pathogenesis and therapy of respiratory insufficiency in neuromuscular diseases. | Q40789061 | ||
| A method to assess energy expenditure in children and adults | Q41603661 | ||
| Effect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patients | Q43065229 | ||
| Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients | Q44276835 | ||
| Energy requirement assessed by doubly-labeled water method in patients with advanced amyotrophic lateral sclerosis managed by tracheotomy positive pressure ventilation. | Q51333827 | ||
| Amyotrophic lateral sclerosis | Q55877676 | ||
| El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a | Q55984319 | ||
| High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: A prospective interventional study | Q58125259 | ||
| Management of ALS: nutritional care | Q71657294 | ||
| Individuals with amyotrophic lateral sclerosis are in caloric balance despite losses in mass | Q71832749 | ||
| Nutritional status is a prognostic factor for survival in ALS patients | Q73016942 | ||
| Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock | Q79931066 | ||
| Dyslipidemia is a protective factor in amyotrophic lateral sclerosis | Q80503053 | ||
| P433 | issue | 9934 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| amyotrophic lateral sclerosis | Q206901 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 2065-2072 | |
| P577 | publication date | 2014-02-28 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial | |
| P478 | volume | 383 |
| Q38830874 | A decrease in blood cholesterol after gastrostomy could impact survival in ALS. |
| Q37305916 | A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. |
| Q39093976 | A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. |
| Q33854270 | Adipokines, C-reactive protein and Amyotrophic Lateral Sclerosis - results from a population- based ALS registry in Germany. |
| Q38715468 | Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism |
| Q57142256 | Amyotrophic lateral sclerosis: the complex path to precision medicine |
| Q52097288 | Anthropometric measures are not accurate predictors of fat mass in ALS. |
| Q47443859 | Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception? |
| Q52687553 | Association Between Body Mass Index and Disease Severity in Chinese Spinocerebellar Ataxia Type 3 Patients. |
| Q64891664 | Association Between Premorbid Body Mass Index and Amyotrophic Lateral Sclerosis: Causal Inference Through Genetic Approaches. |
| Q60637542 | Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis |
| Q28546154 | Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis |
| Q38691517 | Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort |
| Q91651191 | Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics |
| Q38597213 | Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis |
| Q38260277 | Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? |
| Q40719786 | Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival |
| Q48168716 | Comment on: The Awaji criteria are not always superior to the previous criteria: A meta-analysis |
| Q26777929 | Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis |
| Q90647742 | Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1G93A ALS mouse model |
| Q37155949 | Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study |
| Q58630547 | Dietary Lipid Unsaturation Influences Survival and Oxidative Modifications of an Amyotrophic Lateral Sclerosis Model in a Gender-Specific Manner |
| Q42343391 | Diets for Patients with Amyotrophic Lateral Sclerosis: Pay Attention to Nutritional Intervention |
| Q49335981 | Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis |
| Q59794101 | Disease-modifying effects of metabolic perturbations in ALS/FTLD |
| Q92069478 | Editorial: Non-motor Symptoms in Primary Motor Neurological Disorders: From Molecular Pathways to Clinical and Therapeutic Implications |
| Q41597318 | Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. |
| Q52651163 | Energy metabolism in ALS: an underappreciated opportunity? |
| Q38827351 | Enteral feeding in neurological disorders |
| Q90531525 | Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions |
| Q36081558 | Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study |
| Q35555633 | Gene expression changes in spinal motoneurons of the SOD1(G93A) transgenic model for ALS after treatment with G-CSF. |
| Q42377167 | Genetic induction of hypometabolism by ablation of MC4R does not suppress ALS-like phenotypes in the G93A mutant SOD1 mouse model. |
| Q83232835 | Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS |
| Q37014362 | Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet |
| Q56763768 | High-calorie diet might delay amyotrophic lateral sclerosis |
| Q87384369 | High-calorie diets in amyotrophic lateral sclerosis |
| Q48303760 | Hypermetabolism appears to be an adverse prognostic biomarker in amyotrophic lateral sclerosis: a potential for therapeutic intervention? |
| Q88506724 | Hypermetabolism in ALS is associated with greater functional decline and shorter survival |
| Q49659203 | Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. |
| Q33899405 | Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis |
| Q21284703 | Ketogenic diet in neuromuscular and neurodegenerative diseases |
| Q47870164 | Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia |
| Q64076225 | Lipid Biomarkers for Amyotrophic Lateral Sclerosis |
| Q37396449 | Lower versus higher dose of enteral caloric intake in adult critically ill patients: a systematic review and meta-analysis |
| Q38958585 | Management and therapeutic perspectives in amyotrophic lateral sclerosis |
| Q58787868 | Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives |
| Q55237897 | Medium-Chain Fatty Acids, Beta-Hydroxybutyric Acid and Genetic Modulation of the Carnitine Shuttle Are Protective in a Drosophila Model of ALS Based on TDP-43. |
| Q39101800 | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments |
| Q50066234 | Metabolic Dysregulation in Amyotrophic Lateral Sclerosis: Challenges and Opportunities |
| Q64966837 | Metabolic and Stress Response Changes Precede Disease Onset in the Spinal Cord of Mutant SOD1 ALS Mice. |
| Q60949835 | Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS |
| Q38597450 | Motor neuron disease: current management and future prospects |
| Q35623262 | Multidisciplinary Interventions in Motor Neuron Disease |
| Q47784531 | Nanoformulated copper/zinc superoxide dismutase exerts differential effects on glucose vs lipid homeostasis depending on the diet composition possibly via altered AMPK signaling |
| Q40269181 | Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity. |
| Q49334640 | Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease. |
| Q37730973 | No association between gluten sensitivity and amyotrophic lateral sclerosis |
| Q38629090 | Nutrition management methods effective in increasing weight, survival time and functional status in ALS patients: a systematic review |
| Q40820451 | Nutrition with Gastrostomy Feeding Tubes for Amyotrophic Lateral Sclerosis in Canada |
| Q92378843 | Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS |
| Q35239387 | PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. |
| Q35630224 | Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review |
| Q41531607 | Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study |
| Q40385575 | Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study |
| Q96303127 | Potential Preventive Strategies for Amyotrophic Lateral Sclerosis |
| Q35952241 | Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis |
| Q50544849 | Predictive factors for prognosis following unsedated percutaneous endoscopic gastrostomy in ALS patients. |
| Q36444597 | Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo |
| Q49452570 | Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis |
| Q34537070 | Supportive and symptomatic management of amyotrophic lateral sclerosis |
| Q37272856 | Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis |
| Q34389199 | The National ALS Registry: a recruitment tool for research |
| Q57175337 | The Therapeutic Potential of Metformin in Neurodegenerative Diseases |
| Q38577066 | The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. |
| Q38790067 | The measurement and estimation of total energy expenditure in Japanese patients with ALS: a doubly labelled water method study |
| Q42730688 | What is "Hyper" in the ALS Hypermetabolism? |
| Q86000038 | [Nutrition and dietary supplements in neurological diseases] |
Search more.